Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34-mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.
Authors
- İbrahim Halil İnanç (ORCID: https://orcid.org/0000-0003-4046-6748)
- Cezar Iliescu (ORCID: https://orcid.org/0000-0002-8817-4579)
- Özgecan Pırıl Zanbak Mutlu (ORCID: https://orcid.org/0000-0001-9063-360X)
- Deniz Mutlu (ORCID: https://orcid.org/0000-0003-4432-4595)
- Konstantinos Marmagkiolis (ORCID: https://orcid.org/0000-0001-9620-7142)
- Mehmet Cilingiroglu (ORCID: https://orcid.org/0000-0002-6557-2267)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of South Florida (US)
- Tampa General Hospital (US)
- Istanbul University-Cerrahpaşa (TR)
- Minneapolis Heart Institute Foundation (US)
- Kırıkkale University (TR)
Publication Details
- Journal
- US Cardiology Review
- Published
- 2024-11-13
- DOI
- https://doi.org/10.15420/usc.2024.19
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00